Rabacfosadine

DB12762InvestigationalSmall molecule

Rabacfosadine has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin's Lymphoma, and Chronic Lymphocytic Leukemia.

Chemical structure of Rabacfosadine
Formula / weight
C21H35N8O6P · 526.535 g/mol (avg)
Code names
GS-9219

Resolves to

Compound
UNIIM39BO43J9WCAS859209-74-8ChEMBLCHEMBL1823518PubChem16047979
Clinical / RWD
RxNorm2003595
Structure
InChIKeyANSPEDQTHURSFQ-KBPBESRZSA-NSMILESCCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C(NC3CC3)N=C(N)N=C12)N[C@@H](C)C(=O)OCC
Targets
P04293DNA polymerase catalytic subunit

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Rabacfosadine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In